Foresee Pharmaceuticals Co., Ltd. (FP) is a clinical-stage pharmaceutical company. Our mission is to serve patients. We strive to improve patients' quality of life and provide cure through innovative research. We are committed to apply the highest ethical standards to our products, services and communications. Foresee's core competency includes rapid development and commercialization of new drugs using its proprietary drug delivery technology as well as develop first-in-class NCE in disease areas of high unmet medical needs.
FP has two core technologies:
- Drug Delivery Technology： stabilized injectable formulation (SIF), a sustained-release drug delivery platform.
By using our proprietary drug delivery technology (SIF), we are able to rapidly develop new formulations of marketed drugs with significant product differentiation to target the same indications or new indications through the 505(b)(2) regulatory pathway (also known as the hybrid medicinal product in EU). Currently, the products under development are FP-001 (prostate cancer), FP-004 (opiate drug addiction), FP-002 (acromegaly), and FP-008 (diabetic retinopathy).
- Rational Drug Design： novel new drug (New Chemical Entity, NCE) development.
Rationally designed small molecule candidates through medicinal chemistry screening and lead optimization are known as new molecular entities (NMEs) or new chemical entities (NCEs); products currently under development are FP-025 (asthma / chronic obstructive pulmonary disease) and FP-020 (Alport syndrome).
FP currently has two global patent protected new drugs (one new formulation, and one new chemical entity) in clinical trials, namely FP-001 LMIS 50mg (prostate cancer), which is currently being evaluated in a multinational multi-center phase III registration study in the United States, Europe and Taiwan, and FP-025 (a small molecule MMP-12 inhibitor for the treatment of asthma / chronic obstructive pulmonary disease), being studied in a First-in-Human Phase I study in Taiwan. LMIS 50 mg is currently the most advanced clinical asset of Foresee, illustrating the utility of the SIF drug delivery technology, which provides global IP protection. FP-025, as a first-in-class NCE, is being advanced rapidly into clinical proof-of-concept (POC).
FP’s management team consists of seasoned pharmaceutical professionals with many years of industry experience in pharmaceutical R&D and management. To rapidly advance its pipeline products, FP has also teamed up with a network of advisors and consultants in the area of medical, legal, regulatory, business development, and commercial, among others. These advisors and consultants are industry veterans with significant experience and expertise in their respective fields and many are key opinion leaders (KOLs). FP has also established long-term partnerships with commercial contract manufacturers (CMOs) of drug substance and drug product, and other supply chain vendors to manage clinical trial materials and future commercial supplies. These partnerships provide the resources and flexibility required to rapidly advance an asset from research to development and eventually to commercialization.